86 results about "Zika virus" patented technology

The invention discloses a novel application of an RNF6 gene, namely, an application of screening a medicine for preventing and / or treating Zika virus infection, aiming at inhibiting expression of the RNF6 gene or knocking out the RNF6 gene. A series of functional experiments prove that the RNF6 gene promotes the replication of the Zika virus, and the purpose of reducing the replication of the Zika virus can be achieved by using an expression inhibitor of the RNF6 gene or knocking out the RNF6 gene; experimental results show that the RNF6 gene can be used as a potential target for preventing and / or treating Zika virus infection, and a new direction is provided for development of drugs for preventing and / or treating Zika virus infection targeting the RNF6 gene in the future.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The invention relates to the technical field of biology, and provides a primer group and a kit for simultaneously detecting a dengue virus and a Zika virus and application of the primer group, and the primer group is formed and comprises a primer pair 1 aiming at the dengue virus, a primer pair 2 aiming at the Zika virus and a universal LAMP (Loop-Mediated Isothermal Amplification) primer pair. When in use, target virus single-stranded RNA is used as a bridge molecule, under the catalysis of Splint R ligase, adjacent DNA probes with specific sequences are guided and connected, and a double-ring (dumbbell-shaped) structure product containing a general cyclization primer sequence is directly formed. The two key technical breakthroughs of forming a universal double-ring primer through target RNA mediated probe connection and outputting a high-specificity signal dependent on RNase H2 are realized; a dengue virus and Zika virus isothermal nucleic acid amplification detection platform which is simple and convenient to operate, rapid in reaction, high in sensitivity, strong in specificity (capable of effectively avoiding interference of primer dimers and non-specific dyes) and suitable for multiple detection is constructed, and compared with conventional fluorescent quantitative PCR, the dengue virus and Zika virus isothermal nucleic acid amplification detection platform has remarkable advantages.

Provided are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

The present disclosure relates to vaccines and immunogenic compositions comprising an antigen from a Zika virus (e.g., wherein the antigen is an inactivated whole Zika virus), and their use in medical applications (such as methods of treatment).

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

The invention relates to the technical field of biology, and discloses a Zika virus non-structural protein 1 functional site and application thereof in design of a Zika virus attenuated strain. According to the invention, a new Zika virus virulence site is innovatively found, and a basis is provided for research of Zika virus and research and development work of related drugs. The invention also provides an attenuated mutant strain constructed on the basis of the virulence site, and the attenuated mutant strain has obvious attenuated characteristics and higher genetic stability, and can be used as an alternative strain of a Zika virus attenuated live vaccine.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

This invention relates to the field of pharmaceutical technology, disclosing a method for inhibiting Zika virus and its application. The invention identifies CD104 as the binding receptor for Zika virus and demonstrates that CD104 participates in Zika virus invasion of host cells, assisting in the virus's entry into host cells. Therefore, CD104 can provide a new and important target for the development of drugs that inhibit Zika virus invasion. Thus, this invention provides the application of a specific inhibitor of the Zika virus receptor CD104 protein in the preparation of drugs for the prevention or treatment of diseases caused by Zika virus infection.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The invention discloses a nucleic acid molecule for inhibiting Zika virus, a pharmaceutical composition containing the nucleic acid molecule and application. The invention develops an anti-virus strategy for realizing the target host protein based on the RNA structure by changing the bottom-layer anti-virus logic. The MSI1 binding site in the nucleic acid molecule is highly conserved in all Zika virus strains, and the nucleic acid molecule has wide applicability. Meanwhile, the nucleic acid molecule can target an MSI1 high-expression region (namely virus-susceptible tissue), the problem of poor tissue specificity in existing delivery is solved, and the nucleic acid molecule is higher in targeting property, so that the nucleic acid molecule can cope with nervous system infection and pregnancy infection. In addition, the sequence design is relatively simple, and based on natural RNA sequence optimization, the modification demand is reduced, the natural affinity is high, and the chemical modification dependence is greatly reduced.

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to individuals in need thereof.

The application discloses a 3-arylation derivative of indole and a synthesis method and application thereof. 2-methylindole is used as raw material, and after iodization, the raw material is reacted with aryl boronic acid to obtain the target compound. The method has simple synthesis steps and mild reaction conditions, and the 3-arylation derivative of indole has obvious inhibitory effect on Zika virus, and can be expected to be used in potential antiviral drugs.

The application discloses a recombinant adenovirus shuttle plasmid and a preparation method thereof, a recombinant adenovirus and application thereof, and a Zika virus recombinant adenovirus plasmid, and belongs to the field of biological medicines. The Zika virus recombinant adenovirus shuttle plasmid provided by the application takes pShuttle as a carrier, carries a Zika virus E protein mutant gene, and the 5' end of the Zika virus E protein mutant gene is connected with a signal peptide gene; the 5' end of the signal peptide gene is connected with a Kozak sequence; and the 5' end of the Kozak sequence is connected with an enzyme cutting site 1. The recombinant shuttle plasmid, the recombinant plasmid and the recombinant adenovirus provided by the application can be applied to the preparation of a Zika virus adenovirus vaccine, and have wide development and application prospects.

Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and / or preventing broad-spectrum viral infections. Methods of treating and / or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

The invention discloses a synthesis method and application of a non-natural purine base nucleoside drug, and belongs to the field of organic chemistry. According to the method, 4-alkynyl-2-beta-fluorine-5-hydroxymethyl-2-acetic acid oxygen heterocycle and a purine-like non-natural base are taken as raw materials and react in an acetonitrile solution, so that the non-natural purine base glycoside with biological activity can be obtained. According to the invention, a basic group is mainly modified, so that the bioavailability of the medicine is improved, the stability is enhanced, and the drug resistance of nucleoside medicines is improved on the premise of retaining a natural pairing structure. The non-natural purine base nucleoside drug has obvious inhibition on Zika virus, and can be further used in potential antiviral drugs.

The invention provides a construction method and application of a human dopaminergic neuron Zika virus infection model, and belongs to the technical field of disease model preparation. According to the invention, dopaminergic neurons induced by hiPSCs are taken as research objects, and a Zika virus infected human-derived dopaminergic neuron model is established. The human-derived dopaminergic neuron model can be used for effectively screening drugs with antiviral activity. The virus infection model constructed by the invention lays a foundation for effectiveness and safety screening of subsequent drugs.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

This invention relates to the field of biotechnology and discloses the application of mutated gene sites in altering the virulence and / or testicular adaptation of Zika virus. This invention innovatively discovers testicular adaptation sites and novel virulence sites in Zika virus. Mutating these functional sites can yield Zika virus mutant strains with altered virulence and / or testicular adaptation, which is of great significance for Zika virus research, the construction of related animal models, and drug development.

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.

The invention discloses a benzoxazino isoindolone compound as well as a synthesis method and application thereof, and belongs to the field of organic synthesis. A 2-aryl benzoxazine compound 1 and a fluoro methyl acetylenic ketone compound 2 are used as raw materials, and in the presence of a rhodium catalyst, an additive and an organic solvent, a temperature rise reaction is performed to obtain the benzoxazino isoindolone compound 3. A plurality of groups of compounds are screened, and antiviral and anticancer activity tests verify that the compound provided by the invention has the activity of obviously inhibiting proliferation of three cancer cells such as the Zika virus and Hela, A549 and HCT-116, so that the compound provided by the invention has the activity of resisting the Zika virus and has the anticancer activity on cervical cancer, lung cancer and colon cancer.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

The present invention relates to a pharmaceutical composition for prevention or treatment breast cancer, containing a chimeric Zika virus obtained through breast cancer cell passages as an active ingredient.

The invention relates to an application of chlorogenic acid in preparation of an anti-Zika virus drug, and discovers that chlorogenic acid has a very good inhibition effect on Zika virus infection, the half effective inhibition rate EC50 of chlorogenic acid at the cellular level is 15.27 mu M, and the chlorogenic acid has a concentration-dependent effect; meanwhile, the compound has a mechanism of efficiently activating the host I-type interferon to exert virus infection resistance, is relatively safe to host cells, and can be used for preventing and treating Zika virus infection.